Kruppel样因子1-GATA1融合蛋白在体外和体内改善小鼠镰状细胞病表型
本研究探讨2种KLF1-GATA1融合蛋白对血红蛋白表达及镰状细胞病(SCD)表型的纠正作用。在体外,融合蛋白增强人镰状CD34+细胞和SCD小鼠造血干细胞来源红系细胞的δ-珠蛋白与HbA2表达,减少缺氧相关镰变,且不影响红系分化、增殖和去核。在体内,将表达融合蛋白的SCD小鼠造血干细胞移植入SCD小鼠,可减轻贫血、减少红细胞镰变、改善脾肾肝病理改变并恢复尿液浓缩能力。
要点
- KLF1-GATA1融合蛋白增强红系细胞δ-珠蛋白和HbA2表达。
- 融合蛋白减少缺氧相关镰变,不影响红系分化、增殖和去核。
- 移植表达融合蛋白的HSC可改善SCD小鼠贫血、镰变及脏器病理。
核心结论
- 使用KLF1-GATA1融合构建体可能代表血红蛋白病的一种新基因治疗途径。
研究设计与样本
- 研究为体外与体内实验,评估2种KLF1-GATA1融合蛋白对血红蛋白表达及SCD表型的纠正作用。
- 体外使用人镰状CD34+细胞和SCD小鼠造血干细胞(HSC)来源的红系细胞。
- 体内将高度纯化的表达KLF1-GATA1融合蛋白的SCD小鼠HSC移植入SCD小鼠。
主要发现
- 强制表达KLF1-GATA1融合蛋白增强人镰状CD34+细胞和SCD小鼠HSC来源红系细胞的δ-珠蛋白基因和HbA2表达。
- 融合蛋白减少上述红系细胞的缺氧相关镰变,且对红系细胞分化、增殖和去核无影响。
- 移植表达KLF1-GATA1融合蛋白的SCD小鼠HSC可减轻受体小鼠贫血严重程度、减少红细胞镰变。
- 移植表达融合蛋白的HSC改善受体小鼠脾、肾、肝的SCD相关病理改变,并恢复尿液浓缩能力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sickle cell disease (SCD) and β-thalassemia are among the most common genetic disorders worldwide, affecting global health and mortality. Hemoglobin A2 (HbA2, α2δ2) is expressed at a low level in adult blood due to the lack of the Kruppel-like factor 1 (KLF1) binding motif in the δ-globin promoter region. However, HbA2 is fully functional as an oxygen transporter, and could be a valid antisickling agent in SCD, as well as a substitute for hemoglobin A in β-thalassemia. We have previously demonstrated that KLF1-GATA1 fusion protein could interact with the δ-globin promoter and increase δ-globin expression in human primary CD34+ cells. We report the effects of 2 KLF1-GATA1 fusion proteins on hemoglobin expression, as well as SCD phenotypic correction in vitro and in vivo. Forced expression of KLF1-GATA1 fusion protein enhanced δ-globin gene and HbA2 expression, as well as reduced hypoxia-related sickling, in erythroid cells cultured from both human sickle CD34+ cells and SCD mouse hematopoietic stem cells (HSCs). The fusion proteins had no impact on erythroid cell differentiation, proliferation, and enucleation. Transplantation of highly purified SCD mouse HSCs expressing KLF1-GATA1 fusion protein into SCD mice lessened the severity of the anemia, reduced the sickling of red blood cells, improved SCD-related pathological alterations in spleen, kidney, and liver, and restored urine-concentrating ability in recipient mice. Taken together, these results indicate that the use of KLF1-GATA1 fusion constructs may represent a new gene therapy approach for hemoglobinopathies.
引用
- Zhu J, Li H, Aerbajinai W, et al. Kruppel-like factor 1-GATA1 fusion protein improves the sickle cell disease phenotype in mice both in vitro and in vivo. Blood. 2022. PMID: 36399071. doi:10.1182/blood.2021014877
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。